HRP20080027T3 - 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide - Google Patents

4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Info

Publication number
HRP20080027T3
HRP20080027T3 HR20080027T HRP20080027T HRP20080027T3 HR P20080027 T3 HRP20080027 T3 HR P20080027T3 HR 20080027 T HR20080027 T HR 20080027T HR P20080027 T HRP20080027 T HR P20080027T HR P20080027 T3 HRP20080027 T3 HR P20080027T3
Authority
HR
Croatia
Prior art keywords
benzothiazol
morpholin
piperidine
methoxy
amide
Prior art date
Application number
HR20080027T
Other languages
English (en)
Croatian (hr)
Inventor
Flohr Alexander
Moreau Jean-Luc
Maria Poli Sonia
Riemer Claus
Steward Lucinda
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080027(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20080027T3 publication Critical patent/HRP20080027T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20080027T 2004-05-24 2008-01-18 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide HRP20080027T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102262 2004-05-24
PCT/EP2005/005329 WO2005116026A1 (en) 2004-05-24 2005-05-17 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Publications (1)

Publication Number Publication Date
HRP20080027T3 true HRP20080027T3 (en) 2008-05-31

Family

ID=34967309

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080027T HRP20080027T3 (en) 2004-05-24 2008-01-18 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Country Status (39)

Country Link
US (1) US7368446B2 (no)
EP (1) EP1753760B1 (no)
JP (1) JP4668265B2 (no)
CN (1) CN1956983B (no)
AR (1) AR048973A1 (no)
AT (1) ATE382619T1 (no)
AU (1) AU2005247567B2 (no)
BR (1) BRPI0511543B1 (no)
CA (1) CA2567703C (no)
CR (1) CR8703A (no)
CY (1) CY1108104T1 (no)
DE (1) DE602005004142T2 (no)
DK (1) DK1753760T3 (no)
DO (1) DOP2005000091A (no)
EA (1) EA011279B1 (no)
EC (1) ECSP067018A (no)
ES (1) ES2297710T3 (no)
GT (1) GT200500124A (no)
HK (1) HK1105199A1 (no)
HN (1) HN2005000238A (no)
HR (1) HRP20080027T3 (no)
IL (1) IL179364A (no)
MA (1) MA28601B1 (no)
MX (1) MXPA06013417A (no)
MY (1) MY140011A (no)
NO (1) NO336939B1 (no)
NZ (1) NZ550763A (no)
PA (1) PA8633901A1 (no)
PE (1) PE20060274A1 (no)
PL (1) PL1753760T3 (no)
PT (1) PT1753760E (no)
RS (1) RS50574B (no)
SI (1) SI1753760T1 (no)
SV (1) SV2006002125A (no)
TN (1) TNSN06371A1 (no)
TW (1) TWI358297B (no)
UA (1) UA87142C2 (no)
WO (1) WO2005116026A1 (no)
ZA (1) ZA200609136B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DK1578422T3 (da) * 2002-12-20 2007-07-02 Niconovum Ab Fysisk og kemisk stabilt nikotin-indeholdende partikelholdigt materiale
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーNiconovum Ab 改善された嗅ぎたばこ組成物
US20090082341A1 (en) * 2007-07-23 2009-03-26 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
US8168785B2 (en) 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
WO2013156614A1 (en) * 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
WO2016204939A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
JP7287951B2 (ja) * 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのキノキサリン誘導体
ES2940408T3 (es) * 2017-08-21 2023-05-08 Merck Patent Gmbh Derivados de benzoimidazol como antagonistas de los receptores de adenosina
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
US20220088024A1 (en) 2018-12-20 2022-03-24 Biotie Therapies, Inc. Methods for treating cancer using tozadenant
DE102019110904B4 (de) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
NL7109150A (no) 1970-07-06 1972-01-10
US4028374A (en) 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
KR930005004B1 (ko) 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO1990015801A1 (en) 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
DE59005183D1 (de) 1989-11-10 1994-05-05 Agrolinz Agrarchemikalien Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe.
AU653681B2 (en) 1992-05-21 1994-10-06 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
FR2753970B1 (fr) 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
DE69833224T2 (de) 1997-11-10 2006-09-28 Bristol-Myers Squibb Co. Benzothiazole als protein tyrosin-kinase inhibitoren
KR20010015910A (ko) 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
CA2345944A1 (en) 1998-09-30 2000-04-06 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP5053498B2 (ja) 2000-05-12 2012-10-17 コーニング インコーポレイテッド 保護被覆をもつ光ファイバプリフォームを製造する方法
IL153278A0 (en) * 2000-06-21 2003-07-06 Hoffmann La Roche Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives

Also Published As

Publication number Publication date
MA28601B1 (fr) 2007-05-02
PE20060274A1 (es) 2006-04-14
PT1753760E (pt) 2008-02-12
MXPA06013417A (es) 2007-01-23
TWI358297B (en) 2012-02-21
CA2567703A1 (en) 2005-12-08
SV2006002125A (es) 2006-02-15
ATE382619T1 (de) 2008-01-15
CR8703A (es) 2007-10-04
AU2005247567B2 (en) 2010-09-02
BRPI0511543B1 (pt) 2022-05-10
MY140011A (en) 2009-11-30
EP1753760A1 (en) 2007-02-21
SI1753760T1 (sl) 2008-04-30
NZ550763A (en) 2010-07-30
JP4668265B2 (ja) 2011-04-13
GT200500124A (es) 2005-12-26
EP1753760B1 (en) 2008-01-02
DK1753760T3 (da) 2008-04-14
DE602005004142T2 (de) 2009-01-02
CY1108104T1 (el) 2014-02-12
ECSP067018A (es) 2006-12-29
NO336939B1 (no) 2015-11-30
CN1956983A (zh) 2007-05-02
PA8633901A1 (es) 2006-05-16
DE602005004142D1 (de) 2008-02-14
AR048973A1 (es) 2006-06-14
US7368446B2 (en) 2008-05-06
AU2005247567A1 (en) 2005-12-08
EA200602048A1 (ru) 2007-06-29
EA011279B1 (ru) 2009-02-27
ES2297710T3 (es) 2008-05-01
RS50574B (sr) 2010-05-07
NO20065732L (no) 2006-12-22
PL1753760T3 (pl) 2008-06-30
TW200612937A (en) 2006-05-01
UA87142C2 (en) 2009-06-25
CA2567703C (en) 2013-03-05
TNSN06371A1 (fr) 2008-02-22
ZA200609136B (en) 2008-07-30
CN1956983B (zh) 2010-05-26
DOP2005000091A (es) 2005-06-29
US20050261289A1 (en) 2005-11-24
BRPI0511543A (pt) 2008-01-02
IL179364A0 (en) 2007-03-08
IL179364A (en) 2013-01-31
WO2005116026A1 (en) 2005-12-08
JP2008500295A (ja) 2008-01-10
HN2005000238A (es) 2008-07-14
HK1105199A1 (en) 2008-02-06

Similar Documents

Publication Publication Date Title
HRP20080027T3 (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
NO20064077L (no) Kemokinreseptorantagonister
EA200500238A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
ME01992B (me) Jedinjenje diarilhidantoina
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
HRP20080666T3 (en) Cgrp receptor antagonists
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
RS52700B (en) SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND
RS52632B (en) S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
EA200500239A1 (ru) Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
RS53895B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
RS51200B (sr) (imidazol-1-il-metil)-piridazin kao blokator nmda receptora
RS54485B1 (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS